Portfolio News

AOA Dx News Exclusive: Liquid-biopsy startup closes $17M to fund ovarian cancer diagnostic test

Liquid biopsy startup AOA Dx has collected $17 million to support the development of its diagnostic test for ovarian cancer...

AMWELL Enhances Virtual Care Platform with Two Acquisitions: SilverCloud Health and Conversa Health

Transactions Advance Amwell’s Strategy to Enable Health Systems’ and Health Plans’ Telehealth Programs with Ongoing Organic and Inorganic...

The Silicon Review names Conversa as one of the 50 Fastest Growing Companies in the Year 2021

Titled "A Game-Changer: Conversa Health’s Automated Virtual Care Platform was Built to Support the Hybrid-Care Model of the Future" the...

Eirion Therapeutics, Inc. Closes $40 Million Series A Investment and Licensing Deal

Eirion Therapeutics, Inc. Closes $40 Million Series A Investment and Licensing Deal with Shanghai Haohai Biological Technology Ltd.

Automated Virtual Care Platform Conversa Health Expands Series B to $20 Million

Conversa Health, a leading virtual care and triage platform, has expanded its Series B financing to $20 million

Maternity management company Dorsata scores $5.2M in Series A funding

Women’s Health USA, QED Investors, LabCorp, Fool Ventures and Gore Range Capital participated in this round.

Or-Genix Therapeutics Inc. and Fission Labs Announce Partnership for LATAM Dermatology Markets

WORCESTER, Mass.--(BUSINESS WIRE)-- Or-Genix Therapeutics, Inc., a development-stage specialty woman’s health and dermatology company,...

Castle Biosciences Announces Pricing of Initial Public Offering

Castle Biosciences, Inc. announced today the pricing of its IPO of 4,000,000 shares of its common stock at a price of $16/share

Cristina Griffin Joins Or-Genix Therapeutics as Chief Business Officer

Genomic diagnostics provider Castle Biosciences files for a $58 million IPO

Castle Biosciences filed on Wednesday with the SEC to raise up to $58 million in an initial public offering.